Abuse potential assessment of novel central nervous system active and psychedelic substances for controlled substances act scheduling recommendations

The core abuse potential methods that serve U.S. CSA scheduling and global new drug scheduling are generally reliable for many categories of drugs but need to be modified and perhaps supplemented with additional outcome measures to more fully and accurately characterize potential abuse-related risks. This may include behavioral economic assessments in preclinical and clinical studies and a broader range of outcome measures in HAP studies and adverse event assessment in all clinical studies in drug development programs.

Authors

Institutions

Publication Details

Journal
Journal of Psychopharmacology
Published
2025-11-03
DOI
https://doi.org/10.1177/02698811251378511
Citations
3
Primary Topic
Forensic Toxicology and Drug Analysis
Type
article
Field-Weighted Citation Impact
3.92
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abuse potential assessment of novel central nervous system active and psychedelic substances for controlled substances act scheduling recommendations

Ziva D. Cooper, Caitlyn J. Durgin, Ryan K. Lanier, Brenda M. Gannon et al.
3 citations
Journal of Psychopharmacology
Forensic Toxicology and Drug Analysis
3.92
article

Abuse potential assessment of novel central nervous system active and psychedelic substances for controlled substances act scheduling recommendations

Ziva D. Cooper, Caitlyn J. Durgin, Ryan K. Lanier, Brenda M. Gannon, Matthew L. Banks, Justin C. Strickland, Jack E. Henningfield, David J. Heal, Sally L. Huskinson, James K. Rowlett, William E. Fantegrossi, Marion A. Coe, Wendy J. Lynch, Gregory Thomas Collins, Sandra D. Comer, Richard A. Meisch
article en
3 citations

Abstract

The core abuse potential methods that serve U.S. CSA scheduling and global new drug scheduling are generally reliable for many categories of drugs but need to be modified and perhaps supplemented with additional outcome measures to more fully and accurately characterize potential abuse-related risks. This may include behavioral economic assessments in preclinical and clinical studies and a broader range of outcome measures in HAP studies and adverse event assessment in all clinical studies in drug development programs.

Journal of Psychopharmacology
Johns Hopkins University (US), The University of Texas at San Antonio Health Science Center (US), Virginia Commonwealth University (US), Columbia University Irving Medical Center (US), Johns Hopkins Medicine (US), Jackson Memorial Hospital (US), University of Mississippi Medical Center (US), Neurobehavioral Systems (US), South Texas Veterans Health Care System (US), The University of Texas Health Science Center (US), Pinney Associates (United States), University of Virginia (US), University of Bath (GB), University of Arkansas for Medical Sciences (US), The University of Texas Health Science Center at Houston (US)
Openalex Percentile: Top 6%
Forensic Toxicology and Drug Analysis
3.92
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.